Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Analysis of Reportable Segments
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
The analysis of investment activity ratios reveals a divergence between the efficiency of fixed asset utilization and the overall utilization of total assets and equity. While fixed asset efficiency has experienced a sustained decline, both total asset and equity turnovers have shown a gradual improvement over the analyzed period.
- Net Fixed Asset Turnover
- A consistent downward trajectory is evident, with the ratio decreasing from 6.12 in July 2021 to 4.90 by April 2026. This persistent decline indicates a reduction in the revenue generated per unit of net fixed assets, suggesting either an expansion of the fixed asset base that has not yet yielded proportional revenue growth or a decrease in the operational efficiency of physical infrastructure.
- Total Asset Turnover
- The ratio remained relatively stable for the initial phase of the period, fluctuating narrowly between 0.33 and 0.35, before entering a modest growth phase. By April 2026, the ratio reached 0.39, reflecting a slight improvement in the overall efficiency with which the entire asset base is employed to generate sales.
- Equity Turnover
- An upward trend is observed in equity turnover, which rose from 0.61 in July 2021 to 0.74 in April 2026. This growth signifies an increasing ability to generate revenue relative to the shareholders' equity invested in the business, pointing toward enhanced productivity of equity financing.
The contrasting movements between the net fixed asset turnover and the total asset turnover suggest that the decline in fixed asset efficiency is being offset by improvements in the management or composition of other asset categories. The simultaneous rise in equity turnover further indicates that the company is successfully increasing its revenue generation relative to its equity base, despite the diminishing returns on its net fixed investments.
Net Fixed Asset Turnover
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||
| Property, plant, and equipment, net | ||||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||
| Net fixed asset turnover1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Net fixed asset turnover
= (Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026
+ Net salesQ1 2026)
÷ Property, plant, and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
A sustained downward trend is observed in the net fixed asset turnover ratio over the period from July 2021 to April 2026. Although net sales experienced an overall increase, the expansion of the net property, plant, and equipment base occurred at a faster rate, resulting in a decline in the efficiency with which fixed assets are utilized to generate revenue.
- Net Fixed Asset Turnover Trend
- The turnover ratio exhibited a nearly continuous decline, falling from 6.12 in July 2021 to 4.90 by April 2026. The most pronounced reduction occurred between April 2023 and October 2024, where the ratio dropped from 5.61 to 4.85. This trajectory indicates a decrease in the revenue-generating productivity of each dollar invested in net fixed assets.
- Revenue Dynamics
- Net sales grew from $7,987 million in July 2021 to $9,808 million in April 2026. While the long-term trend is positive, the growth was non-linear, characterized by periodic fluctuations. Significant revenue peaks were observed in April 2026 and October 2025, but these increases were insufficient to offset the rising cost of the asset base in terms of the turnover ratio.
- Fixed Asset Accumulation
- There was a consistent and monotonic increase in net property, plant, and equipment, rising from $5,162 million in July 2021 to $7,417 million in April 2026. This steady growth reflects a continuous commitment to capital expenditure and infrastructure expansion throughout the analyzed timeframe.
- Asset Utilization Insights
- The divergence between the growth of fixed assets and the growth of net sales suggests a lag between capital investment and revenue realization. The decline in the turnover ratio implies that the company is operating with an increasing amount of fixed capital relative to its sales volume, which may indicate underutilized capacity or a strategic shift toward long-term scaling that has not yet reached optimal productivity.
Total Asset Turnover
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||
| Total asset turnover1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Total asset turnover
= (Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026
+ Net salesQ1 2026)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of investment activity indicates a gradual improvement in the efficiency of asset utilization from July 2021 through April 2026. While the total asset base remained relatively stagnant, net sales experienced a steady upward trajectory, resulting in a positive trend in the total asset turnover ratio.
- Revenue Generation Efficiency
- The total asset turnover ratio increased from 0.34 in July 2021 to 0.39 by April 2026. This progression suggests an enhanced ability to derive sales from the company's asset base over the observed period, indicating a positive shift in operational productivity.
- Asset Base Stability
- Total assets exhibited minimal volatility, fluctuating within a narrow range between approximately 89.7 billion and 94.1 billion US dollars. Because the asset base did not contract significantly, the improvement in the turnover ratio is attributable to organic sales growth rather than a reduction in the scale of investments.
- Net Sales Growth Patterns
- Net sales grew from 7,987 million US dollars in July 2021 to 9,808 million US dollars in April 2026. The growth was non-linear, characterized by a period of consolidation followed by a notable acceleration beginning in January 2024, which correlates directly with the rise in the turnover ratio from 0.36 to 0.39.
- Comparative Period Analysis
- A period of relative stability was observed between July 2021 and October 2023, during which the turnover ratio fluctuated marginally between 0.33 and 0.35. A distinct positive shift occurred starting in early 2024, marking a transition toward higher efficiency that persisted through the end of the analyzed timeline.
Equity Turnover
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||
| Equity turnover1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Equity Turnover, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Equity turnover
= (Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026
+ Net salesQ1 2026)
÷ Shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of equity turnover reveals a progressive improvement in the efficiency of capital utilization over the observed period. The turnover ratio increased from 0.61 in July 2021 to 0.74 by April 2026, signaling an enhanced ability to generate revenue from the shareholders' equity base.
- Net Sales Performance
- A long-term upward trend in revenue is observed, with net sales rising from 7,987 million in July 2021 to 9,808 million in April 2026. While the growth trajectory includes periodic quarterly fluctuations—specifically notable dips in July 2022 and July 2023—the overall trajectory remains positive, serving as a primary driver for the increase in the turnover ratio.
- Shareholders' Equity Trends
- The equity base remained relatively stable during the first half of the period, peaking at 52,672 million in July 2022. Subsequently, a gradual decline is evident, with equity falling to 49,463 million by April 2026. A more pronounced contraction occurred between January 2024 and April 2024, where equity decreased from 51,792 million to 50,214 million, continuing down to 47,947 million by July 2024.
- Equity Turnover Dynamics
- The equity turnover ratio exhibited a period of relative stagnation between July 2021 and January 2023, fluctuating narrowly between 0.59 and 0.61. A sustained acceleration began in April 2023 and continued through April 2026. This upward movement is the result of a dual effect: the expansion of net sales occurring simultaneously with a contracting equity base, which mathematically elevates the turnover efficiency.
In summary, the transition of the equity turnover ratio from 0.61 to 0.74 indicates a strengthening of investment activity efficiency. The company is generating higher sales volumes relative to its equity, reflecting an optimized alignment between its capital structure and revenue-generating capabilities.